Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 3/20 | 0.52 |
| ▸ | CYCS | P99999 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 4/20 | 0.44 |
| ▸ | CDK8 | P49336 | 4/20 | 0.44 |
| ▸ | ATR | Q13535 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16923680 | 0.87 | TOP1 (0.49) | TOP1CYCSSIGMAR1MKNK1MKNK2 | |
| SCHEMBL17934753 | 0.84 | TOP1 (0.46) | TOP1CYCSATRHTR2B | |
| SCHEMBL17934754 | 0.84 | TOP1 (0.75) | TOP1CYCSKDM4EENPP2 | |
| SCHEMBL16920383 | 0.82 | TOP1 (0.44) | TOP1CYCSKDM4EHTR2B | |
| SCHEMBL17934752 | 0.82 | TOP1 (0.60) | TOP1CYCSENPP2 | |
| SCHEMBL15258312 | 0.80 | TOP1 (0.81) | TOP1CYCSKDM4EENPP2 | |
| SCHEMBL4413776 | 0.80 | TOP1 (0.53) | TOP1CYCSENPP2 | |
| SCHEMBL26401166 | 0.79 | JAK3 (0.47) | TOP1CYCSKDM4EKDR | |
| SCHEMBL19888947 | 0.79 | TOP1 (0.56) | TOP1CYCSL3MBTL1ENPP2 | |
| SCHEMBL16920365 | 0.79 | TOP1 (0.56) | TOP1CYCSENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3185901-B1 | COMPOUND AND METHOD | PCI BIOTECH AS (NO) | 2023-10-04 | — | — | EP | disclosed |
| US-9901636-B2 | Conjugate of a photosensitiser and chitosan and uses thereof | PCI BIOTECH AS (NO) | 2018-02-27 | — | — | US | disclosed |
| US-20170252441-A1 | COMPOUND AND METHOD | PCI BIOTECH AS (NO) | 2017-09-07 | — | — | US | disclosed |
| US-20160206725-A1 | COMPOUND AND METHOD FOR VACCINATION AND IMMUNISATION | PCI BIOTECH AS (NO) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170252441-A1 | COMPOUND AND METHOD | CSF3R, IL2, IL5 | TOP1 2013/4885CYCS 2836/4885SIGMAR1 4410/4885 |
| US-20160206725-A1 | COMPOUND AND METHOD FOR VACCINATION AND IMMUNISATION | TLR9, TLR3, TLR1 | TOP1 3662/4885CYCS 4582/4885SIGMAR1 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.